Session 1: Pathogenesis
Lead discussant: Yehuda Chowers, Haifa, Israel
Exposome
Genetics
Inflammatory pathways
Session 2: Part I: Case-based management of IBD therapies
Lead discussant: Peter Irving, London, United Kingdom
5-ASA compounds
Thiopurines
Methotrexate
Steroids
Anti-TNF agentes
Anti-integrines
Session 2: Part II: New biologics and small molecules
Lead discussant: Axel Dignass, Frankfurt, Germany
Ustekinumab
Tofacitinib
Other small molecules (apremilast/ozanimod)